This recombinant monoclonal antibody is developed as a research-grade biosimilar to IBI-325, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through inhibition of T cell and natural killer cell function while enhancing regulatory T cell activity. Elevated NT5E expression is associated with multiple cancers, including triple-negative breast cancer, melanoma, and ovarian cancer, where it correlates with poor prognosis and immune evasion.
IBI-325 is a therapeutic antibody designed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression and potentially restoring anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating NT5E-mediated immune regulation, tumor microenvironment dynamics, and combination immunotherapy strategies. It supports studies examining checkpoint inhibition mechanisms and adenosine pathway modulation in oncology and immunology research.
Email: support@cusabio.com
Distributors Worldwide